RK
RKT.LSE Reckitt Benckiser Group PLC
- Market cap
- GBX 35.0B
- P/E
- 12.4x
- P/B
- 6.04x
- ROE
- 46.0%
- Dividend yield
- 3.88%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is RKT.LSE undervalued?
Graham numberRKT.LSE trades 82.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Reckitt Benckiser Group PLC fundamental analysis
No fundamental analysis for Reckitt Benckiser Group PLC yet.
Reckitt Benckiser Group PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Reckitt Benckiser Group PLC
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne…
Full company profileReckitt Benckiser Group PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Reckitt Benckiser Group PLC annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 9.48B | 11.4B | 12.6B | 12.8B | 14.0B | 13.2B | 14.5B | 14.6B | 14.2B | 14.2B | 25.6B |
| Gross Profit | 5.80B | 6.98B | 7.64B | 7.78B | 8.44B | 7.69B | 8.36B | 8.76B | 8.60B | 8.49B | 14.9B |
| Operating Income | 2.27B | 2.74B | 3.05B | 3.29B | 2.16B | -804M | 3.25B | 2.53B | 2.43B | 3.42B | 4.66B |
| EBITDA | 2.49B | 3.02B | 3.51B | 3.80B | 3.62B | 436M | 3.90B | 3.19B | 2.95B | 3.92B | 6.23B |
| Net Income | 1.83B | 3.38B | 2.16B | -2.77B | 1.19B | -32.0M | 2.33B | 1.64B | 1.43B | 3.18B | 2.61B |
| EPS | 2.56 | 4.75 | 3.05 | -3.91 | 1.66 | -0.04 | 3.25 | 2.29 | 2.03 | 4.87 | 4.02 |
| Balance Sheet | |||||||||||
| Total Assets | 18.0B | 37.0B | 37.7B | 32.1B | 31.3B | 26.9B | 28.7B | 27.1B | 25.3B | 25.1B | 24.4B |
| Total Liabilities | 9.59B | 23.4B | 22.9B | 22.7B | 22.1B | 19.5B | 19.3B | 18.7B | 18.6B | 17.3B | 18.7B |
| Shareholders' Equity | 8.42B | 13.5B | 14.7B | 9.36B | 9.12B | 7.40B | 9.44B | 8.45B | 6.70B | 7.75B | 5.67B |
| Cash & Short-term Investments | 885M | 2.13B | 1.48B | 1.55B | 1.65B | 1.26B | 1.16B | 1.39B | 760M | 1.95B | 878M |
| Total Debt | 2.39B | 12.9B | 12.2B | 12.2B | 10.6B | 9.56B | 8.88B | 8.54B | 8.66B | 8.43B | 10.2B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 2.42B | 2.49B | 2.45B | 1.41B | 3.52B | 1.70B | 2.40B | 2.64B | 2.68B | 2.30B | 2.46B |
| Capital Expenditure | 176M | 286M | 437M | 443M | 486M | 450M | 443M | 449M | 465M | 536M | 696M |
| Free Cash Flow | 2.25B | 2.21B | 2.02B | 968M | 3.03B | 1.25B | 1.95B | 2.19B | 2.22B | 1.76B | 1.76B |
| Ratios | |||||||||||
| ROE | 21.8% | 24.9% | 14.7% | -29.6% | 13.0% | -0.4% | 24.7% | 19.4% | 21.3% | 41.1% | 46.0% |
| ROA | 10.2% | 9.1% | 5.7% | -8.6% | 3.8% | -0.1% | 8.1% | 6.1% | 5.6% | 12.7% | 10.7% |
| Net Profit Margin | 19.3% | 29.5% | 17.2% | -21.6% | 8.5% | -0.2% | 16.1% | 11.2% | 10.1% | 22.4% | 10.2% |
| Debt to Equity | 0.28x | 0.95x | 0.82x | 1.30x | 1.16x | 1.29x | 0.94x | 1.01x | 1.29x | 1.09x | 1.79x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Reckitt Benckiser Group PLC dividends
- Dividend yield
- 3.88%
- Forward dividend
- 2.16 GBX
- Payout ratio
- 44.1%
- Ex-dividend date
- Aug 6, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | GBP 1.40B | 2.15 | 44.1% |
| 2024 | GBP 1.38B | 1.97 | 96.8% |
| 2023 | GBP 1.34B | 1.86 | 81.5% |
| 2022 | GBP 1.25B | 1.74 | 53.6% |
| 2021 | GBP 1.25B | 1.75 | - |
| 2020 | GBP 1.24B | 1.74 | 104.5% |
| 2019 | GBP 1.23B | 1.73 | - |
| 2018 | GBP 1.19B | 1.67 | 54.9% |
| 2017 | GBP 1.13B | 1.59 | 33.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 24:25 on Feb 2, 2026.
Who owns Reckitt Benckiser Group PLC
- Insiders 0.16%
- Institutions 71.11%
- Public & others 28.73%
- Shares outstanding 633M
- Free float 630M
Reckitt Benckiser Group PLC company profile
- Company name
- Reckitt Benckiser Group PLC
- Ticker
- RKT.LSE
- ISIN
- GB00BSZBP530
- Exchange
- London Exchange
- Sector
- Consumer Defensive
- Industry
- Household Products
- Employees
- 36,200
- Fiscal year end
- December
- Address
- Turner House, Slough, United Kingdom, SL1 3UH
- Phone
- 44 17 5321 7800
- Website
- reckitt.com
About Reckitt Benckiser Group PLC
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne, Digestive-Advantage, Movefree, and neuriva names; stain removal under Vanish brand name; and disinfectant products under the Finish, Harpic, and Lysol brands. In addition, the company offers nutritious complementary foods and milk formulas for infant and young children under the Enfamil and Nutramigen brands. Reckitt Benckiser Group plc was founded in 1819 and is headquartered in Slough, the United Kingdom.
Reckitt Benckiser Group PLC management
10- Mr. Kristoffer Loe LichtCEO & Executive Director · born 1976
- Ms. Shannon Sue EisenhardtCFO & Executive Director · born 1974
- Mr. Nicholas James Ashworth C.F.A.Senior Vice President of Investor Relations
- Ms. Catheryn O'RourkeSenior VP, General Counsel & Company Secretary · born 1973
- Ms. Sheila RedzepiChief Communications & Corporate Affairs Officer · born 1979
- Mr. Ranjay RadhakrishnanChief Human Resources Officer · born 1971
- Mr. Jerome LemairePresident North America · born 1974
- Ms. Angela Naef Ph.D.Chief Research & Development Officer · born 1976
- Ms. Susan SholtisPresident of Nutrition · born 1967
- Dr. Alessio Fasano M.D.Chief Science & Medical Officer of Mead Johnson Nutrition (MJN) Business